Upside – $VEEA +45.0% (regained full Nasdaq listing compliance following its reverse stock split) – $XRTX +21.0% (outlined planned FDA IND and Health Canada clinical-trial filings for XRx-026 in gout) – $SAIQ +19.5% (confirmed an October satellite launch advancing its post-quantum secure-communications roadmap) – $HUM +14.5% (2027 CMS Star Ratings exceeded its top-quartile revenue goal, …
Read in context ›XORTX Therapeutics Inc Stock (XRTX)
Track XORTX Therapeutics Inc stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
XRTX
XORTX Therapeutics Inc
$1.62
▼ -2.62 (-58.59%) past year
Market Cap
—
P/E Ratio
—
1Y Return
-58.59%
EPS (TTM)
—
Read the latest TheStreet Pro articles mentioning XORTX Therapeutics Inc, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning XRTX yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning